likely to have VWINGS in use at last follow-up (P < .007). No differences in use were found between clinic providers. A total of 77 (12%) patients had at least one device removed. Reasons for explantation were 28.6% infection, 26% cannulation difficulties, 11.7% device moved, 11.7% no longer needed, 6.5% excessive scarring, and 15.6% unknown. A total of 44 patients (6.7%) had a secondary procedure, not including catheter placement. There were no known fistula failures due to device placement or removal. Fistula survival was 87%. Failure of 84 fistulas (12.8%) occurred an average of 254 days after implantation.
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Outcomes of Forearm Loop Grafts and the
Objectives: Preservation of potential hemodialysis (HD) access sites is an emphasis of current guidelines as patients may experience multiple access failures during their lifetime. When forearm vein is inadequate for radiocephalic arteriovenous fistula (AVF) creation, current guidelines favor upper arm AVF, but this approach may sacrifice potential HD access sites. We hypothesized that forearm loop grafts (fAVG) have acceptable patency and create additional access sites by dilating the upper arm basilic and cephalic vein.
Methods: We retrospectively reviewed all HD access procedures at a single academic institution from September 2009 to December 2015. Outcomes of fAVG were compared with upper arm AVF. Forearm AVFs and upper arm AVGs were excluded from the analysis. We compared primary and cumulative patency between the two co-cohorts. Forearm AVGs were evaluated with preoperative vein mapping to determine whether there was adequate upper arm cephalic and/or basilica vein at the time of graft insertion. Additionally, we evaluated patients with failed fAVG an increase in potential ipsilateral access sites after fAVG failure, defined as ipsilateral cephalic or basilic upper arm vein $3 mm by duplex vein mapping.
Results: Thirty-six fAVGs and 163 upper arm AVFs were created during the study period. In the fAVG cohort, 28 were inserted with ipsilateral cephalic and/or basilic upper arm vein <3 mm, and eight were inserted with ipsilateral upper arm vein $3 mm. Primary and cumulative patency of fAVG with $3 mm upper ipsilateral arm vein were similar to upper arm AVF (Table) . The primary and cumulative patency at 6 months and 1 year are noted in the Table. One-third (3 of 9) patients in the fAVG cohort with <3 mm cephalic and/or basilica vein experienced dilation of the upper arm ipsilateral cephalic and/or basilic veins to $3 mm after AVG failure. The average increase vein diameter was 0.7 6 1.3 mm. Reasons for not observing an increase of ipsilateral vein diameter after fAVG failure include <3 months of a patent forearm loop graft, stenting across the outflow vein across the elbow, and initial vein caliber <2 mm.
Conclusions: Our results demonstrate fAVG with $3 mm ipsilateral upper arm vein at time of insertion have similar patency to upper arm AVG, thereby preserving future HD access sites. In circumstances when upper arm vein is <3 mm, fAVG insertion may provide an additional benefit of increasing HD access sites via dilation of upper arm veins in one-third of patients. Objectives: Thoracic endovascular aortic repair (TEVAR) has become the treatment of choice for aortic dissections in many centers. While adequate proximal seal is a fundamental requisite for TEVAR, there are insufficient data on the impact of the proximal seal length on patient outcomes. The goal of this study was to describe the proximal seal zone achieved during TEVAR for aortic dissections as well as its effect on clinical outcomes and aortic remodeling.
Methods: A retrospective review was performed on all patients who underwent TEVAR for aortic dissections at a single institution from 2006 to 2016. Preoperative computed tomography (CT) was used to identify the entry tear, extent of dissection, and distances between the arch branches in three-dimensional centerline. Proximal seal zone length was calculated on postoperative imaging. Sequential postoperative CT scans were analyzed for remodeling of the true and false lumen aortic diameters over time. Clinical outcomes, including retrograde type A dissection (RTAD), death, and aortic reinterventions, were recorded.
Results: During the study period, 84 patients underwent TEVAR for aortic dissections. Indications for TEVAR were malperfusion (n ¼ 12), aneurysm (n ¼ 26), persistent pain (n ¼ 33), rupture (n ¼ 8), uncontrolled hypertension (n ¼ 2), and other (n ¼ 3). Mean follow-up was 14 months (range, 0-94 months). In 28 patients (33%), the aorta proximal to stent graft was without intramural hematoma, while the proximal seal zone in 56 patients (67%) was entirely in intramural hematoma. Proximal seal according to the manufacturers' instructions for use (2 cm of normal 
